By Julie Steenhuysen and Michael Erman (Reuters) - An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immuno.
An experimental mRNA cancer vaccine
developed by Moderna Inc and Merck & Co cut the
risk of death or recurrence of the most deadly skin cancer by
44% compared with Merck s immunotherapy Keytruda. | April 16, 2023
An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44% compared Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.
An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co s blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44%